

For Immediate Release

TSX Exchange Symbol: **RVX**

Resverlogix Collaborates NexVas™ AD Program with Leading Alzheimer's Researcher at Sun Health Research Institute

Dr. Larry Sparks first to identify the link between cholesterol and Alzheimer's disease

Calgary, AB June 19, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that it has signed a collaborative research agreement with Dr. Larry Sparks of the Sun Health Research Institute (SHRI) to study Resverlogix’s novel ApoA-I enhancing therapy for the treatment of Alzheimer’s Disease (AD).

“My previous clinical trial data in AD patients coupled with findings in animal studies clearly indicate that raising ApoA-I/HDL levels could be of benefit in treating and perhaps preventing the dementing disorder. I look forward to working with Resverlogix and their novel ApoA-I therapy, NexVas™ AD, as a potential new approach for the treatment for Alzheimer’s and cognitive impairment,” stated Larry Sparks, Ph.D. senior scientist and head of the Dr. Ralph and Muriel Roberts Laboratory for Neurodegenerative Disease Research at Sun Health Research Institute.

Dr Jan Johansson, Senior Vice President of Clinical Affairs of Resverlogix stated, “We are pleased to begin work with Dr. Sparks who is the pioneer in the field of Alzheimer’s and its relationship to lipids, including ApoA-I and HDL. There is a growing body of evidence that has demonstrated the protective role of ApoA-I in neurodegenerative diseases such as Alzheimer’s.”

Dr. Sparks was the first to discover the neuropathologic link between cholesterol and Alzheimer’s disease. In a three-year study at the Institute’s Cleo Roberts Center for Clinical Research it was confirmed in nationwide clinical trials that elevated cholesterol levels might predict which aging seniors are more at risk of developing Alzheimer’s disease. In a separate study directed by Dr. Sparks, it was demonstrated that Lipitor®, a cholesterol-lowering medication, slows the progression and reduces the deterioration of Alzheimer’s Disease.

For more than 20 years Sun Health Research Institute (SHRI) has been a leader nationally and internationally in the effort to find answers to disorders related to aging including Alzheimer’s disease, Parkinson’s disease, arthritis and prostate cancer. The Institute, founded in 1986, together with its Arizona consortium partners, has been designated by the National Institutes of Health as one of just 29 Alzheimer’s Disease Centers in the United States. SHRI’s Cleo Roberts Center for Clinical Research takes laboratory discoveries to clinical trials that foster hope for new treatments. SHRI is affiliated with the Sun Health non-profit community healthcare network.

Neurodegenerative diseases such as Alzheimer’s are one of the most debilitating in the developed world with an estimated prevalence in the United States alone to grow to 15 million people in the US alone by 2050. In a report commissioned by the Alzheimer’s Association, caregiver costs in the United States are estimated at US \$36.5 billion which includes loss of productivity, absenteeism and worker replacement. The indirect costs of AD would also be greatly reduced; it is estimated that one-half to two-thirds of the cost of AD care stems from unpaid caregivers (often family members), who spend 16-35 hours per week looking after a person with AD. These figures underscore the importance of developing new therapies to aide in the socioeconomic burden of AD.

About Resverlogix Corp.

Suite 202

279 Midpark Way SE

Calgary AB T2X 1M2

P 403.254.9252

F 403.256.8495

info@resverlogix.com

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that enhance ApoA-I to address atherosclerosis, the main underlying cause of cardiovascular disease (CVD). The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com